Skip to main content
AARD
NASDAQ Life Sciences

Q3 Loss Widens to 88 Cents a Share, Missing Consensus by 16 Cents

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.52
Mkt Cap
$33.265M
52W Low
$0.93
52W High
$16.6
52W Position info
63% above low
Off High info
91% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

AARD sits 63% above its 52-week low of $0.93 on light trading volume (0.4× avg).

Summary

Aardvark posted an adjusted loss of 88 cents a share for the September quarter, worse than the 72-cent consensus of eleven analysts and wider than the 75-cent loss a year earlier. Revenue was zero, as expected for a pre-commercial biotech. The net loss came to $19.19 million, consistent with the 10-Q filed earlier today showing $60.3 million in cash and investments — enough to fund operations through 2027 only if the Phase 3 ARD-101 program stays paused. Research and development spending for the quarter was $15.7 million. The stock has lost 71.2% this quarter and 88.4% this year, and one analyst cut estimates in the past 30 days. The offsetting item remains the October FDA decision lifting the clinical hold on ARD-101 for Prader-Willi syndrome, with PWS trials expected in 2027, which is the real driver of the story from here.

At the time of this announcement, AARD was trading at $1.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.3M. The 52-week trading range was $0.93 to $16.60. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

AARD - Latest Insights

AARD
Nov 13, 2026, 8:18 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $1.52 info
Change: $0 (0%) info
Market Cap: $33.265M info
AARD
Nov 12, 2026, 7:56 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.51
Real-time Price: $1.52 info
Change: +$0.0097 (+0.64%) info
Market Cap: $33.265M info
AARD
Oct 23, 2026, 8:38 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.09
Real-time Price: $1.52 info
Change: -$1.57 (-51%) info
Market Cap: $33.265M info
AARD
Oct 22, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.95
Real-time Price: $1.52 info
Change: -$2.43 (-62%) info
Market Cap: $33.265M info
AARD
Aug 11, 2026, 5:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.33
Real-time Price: $1.52 info
Change: -$5.81 (-79%) info
Market Cap: $33.265M info